Orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B)Binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Here, MARK2 is linked to neoplasm.